Company Insights

TOMZ customer relationships

Explore interactive graphBrowse insights index

TOMZ customers relationship map

TOMI Environmental Solutions (TOMZ): Customer Relationships that Drive SteraMist Adoption

TOMI sells, licenses and services the SteraMist decontamination platform—equipment, consumables and validation services—primarily to life‑science, government, healthcare and industrial customers. Revenue is generated through one‑time system sales, recurring service and consumable sales, and strategic OEM integrations that embed TOMI’s ionized hydrogen peroxide (iHP) technology into third‑party cleanroom and biosafety enclosures. For investors, TOMI’s go‑to‑market mixes direct sales, channel/distributor wins and OEM partnerships that scale distribution without heavy long‑term contract exposure.
Visit https://nullexposure.com/ for an organized view of these customer relationships and source documents.

Why customers buy: a concise commercial thesis

TOMI monetizes through equipment and validation service contracts centered on its patented BIT/iHP technology, then captures repeat revenues from consumables, support and franchise/service network partnerships. OEM integrations and preferred regional partners amplify distribution, while targeted government and CDMO wins deliver mission‑critical credibility that supports higher‑margin services.

Operating constraints that shape the business model

Several company‑level signals in TOMI’s filings and releases illuminate the operating posture investors should price into TOMZ:

  • Contracting posture: short‑term sales orientation. TOMI discloses it does not have long‑term contracts with customers and cannot rely on backlog as a revenue predictor, which profiles the business as transactional and sales‑driven (evidence from TOMI’s 2024 Form 10‑K).
  • Geographic reach is global but U.S.‑centric in dollars. TOMI maintains registrations in all 50 states, DC, Canada and ~40 other countries; U.S. revenue represented the bulk of reported sales in 2024 (Form 10‑K revenue table).
  • Single product dependency. TOMI reports a single reportable segment driven by the SteraMist product family, making the company’s economics highly concentrated on one technology platform (Form 10‑K).
  • Multi‑role commercial model. TOMI functions as licensor, seller and service provider for SteraMist, enabling multiple monetization paths (Form 10‑K language).

These constraints produce a business where distribution breadth, repeat consumable/service attach and franchise/OEM channels determine growth trajectory more than long‑duration contract economics.

Customer map: who’s using and integrating SteraMist

Below I list every named relationship reported in TOMI’s public materials and summarize TOMI’s engagement in plain English with source context.

  • Bonneville Joint School District No. 93 — In November 2024 the Idaho school district integrated SteraMist technology into its cleaning protocols, illustrating education sector adoption. Source: TOMI 2024 Form 10‑K (tomz-2024-12-31).
  • BeSpoke Pharmaceuticals — TOMI reported that a partner sold a second SteraMist Hybrid System to BeSpoke, a Nevada manufacturer focused on 503B products, extending TOMI into compounding pharma manufacturing. Source: TOMI 2024 Form 10‑K (tomz-2024-12-31).
  • EMEA Group, Inc. — TOMI disclosed a sale of twenty SteraMist Environment Systems to EMAQ/EMEA Group generating $1,180,280 in revenue on July 24, 2024; a meaningful enterprise order. Source: TOMI 2024 Form 10‑K (tomz-2024-12-31).
  • Indigo Pharmaceutical, Inc. — TOMI recorded a sale of an Environment System plus validation services for a vivarium facility in Mexico to Indigo, identified as a large private pharmaceutical client. Source: TOMI 2024 Form 10‑K (tomz-2024-12-31).
  • Pfizer, Inc. — TOMI lists Pfizer among supported clientele and ongoing facility engagements, signaling blue‑chip pharma referenceability. Source: TOMI 2024 Form 10‑K (tomz-2024-12-31).
  • St. Jude Hospital — A customer since 2021, St. Jude expanded its deployment by adding three SteraMist Surface Units in 2024, an example of expansion revenue within a single facility. Source: TOMI 2024 Form 10‑K (tomz-2024-12-31).
  • Crank and Boom — TOMI entered the desserts/ice cream industry in 2024 with Crank and Boom as a named customer, broadening use cases into foodservice hygiene. Source: TOMI 2024 Form 10‑K (tomz-2024-12-31).
  • Lakeview Farms — Named as a 2024 customer in the desserts/ice cream category, showing adoption in food manufacturing. Source: TOMI 2024 Form 10‑K (tomz-2024-12-31).
  • Mayorga Coffee — TOMI entered the coffee industry in 2024 with Mayorga Coffee, reflecting outreach into beverage processing. Source: TOMI 2024 Form 10‑K (tomz-2024-12-31).
  • National Institute of Forensic Medicine (IPFN) in Malaysia — TOMI secured a contract with Malaysia’s IPFN on October 24, 2024, evidencing government/institutional adoption in APAC. Source: TOMI 2024 Form 10‑K (tomz-2024-12-31).
  • Organea Terra SRL — TOMI reported Organea Terra in the coffee industry expansion, signaling international commercial penetration. Source: TOMI 2024 Form 10‑K (tomz-2024-12-31).
  • NASA — TOMI highlights selection by NASA for a biosecurity operation, positioning TOMI as a supplier for mission‑critical government environments (reported in full‑year 2025/2026 releases). Source: GlobeNewswire / company release (2026) and Sahm Capital coverage.
  • NASA Johnson Space Center — TOMI cited deployments at NASA Johnson Space Center in a FY2026 business update tied to brand and commercial momentum. Source: TradingView summary of company releases (FY2026).
  • Trauma and Casualty Team (T.A.C.T.) — TOMI announced the purchase of SteraMist iHP equipment and BIT Solution totaling $175,000 by T.A.C.T. franchises (18 U.S. franchises), demonstrating traction in professional decontamination services (announced Oct 1, 2025). Source: GlobeNewswire / The Globe and Mail / QuiverQuant (FY2025–FY2026).
  • Trauma and Casualty Team (T.A.C.T.) franchises — Coverage repeated across press channels confirming the $175k franchise expansion order. Source: QuiverQuant / GlobeNewswire (FY2025–FY2026).
  • Steelco / Steelco S.p.A. — Listed as an OEM integration partner embedding iHP into cleanroom enclosures and biosafety cabinets in TOMI’s FY2026 disclosures. Source: TradingView / GlobeNewswire (FY2026).
  • Pharma Biotech System Components (PBSC) — Named as a strategic OEM partner for custom integrations driving platform growth. Source: GlobeNewswire (FY2025–FY2026).
  • Nuaire / Nuaire, Inc. — Identified as an OEM partner integrating iHP into enclosures, supporting TOMI’s Europe/North America distribution push. Source: GlobeNewswire / TradingView (FY2025–FY2026).
  • Getinge / Getinge AB — Included among strategic OEM partners in TOMI’s integration pipeline and referenced in FY2025–FY2026 releases. Source: GlobeNewswire / TradingView / Sahm Capital (FY2025–FY2026).
  • DisinfectCare — TOMI’s long‑standing partner DisinfectCare facilitated SteraMist service implementation at a major Mexican dairy facility, evidencing channel execution internationally. Source: GlobeNewswire press release (March 2026).
  • Ster‑Pharma — Netherlands partner since 2019 positioned to accelerate SteraMist entry into EU sectors following EU authorization events noted in FY2026 press coverage. Source: QuiverQuant (FY2026).
  • Thermo Fisher Scientific (TMO) — TOMI lists Thermo Fisher among supported facilities, showing engagement with a major life‑science tools company. Source: TOMI 2024 Form 10‑K (tomz-2024-12-31).
  • EMEA / EMAQ Group, Inc. — The July 24, 2024 sale to EMAQ/EMEA (20 systems) is a material order that produced >$1.1M revenue. Source: TOMI 2024 Form 10‑K (tomz-2024-12-31).
  • Hudson Global Ventures, LLC — Not a customer but a financing relationship: TOMI’s announced equity line of credit gives Hudson the right to purchase up to $20M in common stock over 24 months, a capital markets linkage. Source: GlobeNewswire registration statement release (Nov 2025).
  • ESCO / ESCO Micro Pte. Ltd. — Cited among strategic enclosure OEM partners in TOMI’s integration pipeline and custom integration announcements. Source: GlobeNewswire / TradingView (FY2025–FY2026).
  • Ares Scientific — East Coast distributor partner that delivered a new university client and SIS platform sale in August 2025, reflecting distributor‑driven field growth. Source: GlobeNewswire Q3‑2025 release (FY2025).
  • Total Clean Air / Total Clean Air Limited (TCA) — Appointed TOMI’s Preferred European Partner for SteraMist iHP and integrated iHP into TCA’s modular cleanroom platform; multiple press releases detail UK/EU positioning and commercial contracts. Source: GlobeNewswire / MarketScreener / company press (FY2025–FY2026).

Investment implications and key takeaways

  • Concentration on one core product creates leverage but also single‑technology risk. Growth depends on SteraMist adoption across verticals.
  • OEM and preferred regional partner strategy is the practical lever to scale distribution internationally without long fixed contracts. Total Clean Air, Getinge, ESCO, Steelco, PBSC and Nuaire are central to that play.
  • Government and blue‑chip pharma engagements (NASA, Pfizer, Indigo, Thermo Fisher) function as high‑value references that de‑risk broader adoption in regulated environments.
  • Revenue remains transactional with short contract tenor, so quarterly performance will track order flow, channel execution and EMEA/Asia deployments.

For a consolidated dossier of the underlying filings and press releases cited above, visit https://nullexposure.com/. Investors evaluating TOMZ should weight channel expansion and OEM pipeline execution more heavily than backlog stability when modeling future revenue.

Join our Discord